A class of antibodies that target a specific pro-inflammatory cell-signaling protein (termed IL-12/23p40) and are used to treat psoriasis also show beneficial effects in mouse models of Alzheimer's disease (AD), according to a study published online this week in Nature Medicine.
Increased inflammation is thought to be both a cause and consequence of Alzheimer's disease. Although the pro-inflammatory cell-signaling proteins (or, cytokines) interleukin-12 (IL-12) and IL-23-both of which share the subunit IL-12/23p40-drive autoimmune diseases, it remains unclear whether they contribute to AD pathogenesis.
Frank L. Heppner, Burkhard Becher, and colleagues found that IL-12, IL-23 and the shared subunit IL-12/23p40 are released by non-neuronal resident cells of the brain, called glia, and are detected at elevated levels in the brains of mice engineered to develop AD. Mice lacking each of these cytokines or a shared receptor show reduced AD-like pathology. Therapeutically, when the authors gave the mice antibodies specific for the shared IL-12/23p40 subunit either early on or after disease is established, they found that there was reduced pathology and improved memory in cognitive tasks.
Moreover, the clinical relevance of these findings is bolstered by data from individuals with AD, showing a correlation between IL-12/23p40 levels in the cerebrospinal fluid and cognitive performance.
COVID-19: Shielding may not be as effective as expectedScientific Reports
Medical research: Lack of sex and gender variables in many COVID-19 clinical studiesNature Communications